KAS
SUPN icon

Kestra Advisory Services’s Supernus Pharmaceuticals SUPN Stock Holding History

Kestra Advisory Services’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243K Buy
5,224
+892
+21% +$42.8K ﹤0.01% 2958
2026
Q1 		$224K Sell
4,332
-1,124
-21% -$57.2K ﹤0.01% 2861
2025
Q4 		$271K Sell
5,456
-2,018
-27% -$98.1K ﹤0.01% 2624
2025
Q3 		$357K Sell
7,474
-732
-9% -$29.5K ﹤0.01% 2303
2025
Q2 		$259K Buy
8,206
+30
+0.4% +$961 ﹤0.01% 2466
2025
Q1 		$268K Sell
8,176
-618
-7% -$21.9K ﹤0.01% 2250
2024
Q4 		$318K Buy
+8,794
New +$310K ﹤0.01% 2178

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Kestra Advisory Services's SUPN Position: Q2 2026 in Review

Kestra Advisory Services increased its Supernus Pharmaceuticals (SUPN) stake by 21% in Q2 2026, buying an estimated $42.8K and bringing the position to 5,224 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #2958.

Kestra Advisory Services first reported a position in SUPN in Q4 2024 and has held it in 7 quarters since. The position peaked at $357K in Q3 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Kestra Advisory Services held 5,224 shares of Supernus Pharmaceuticals worth $243K as of Q2 2026.
  • Kestra Advisory Services bought 892 Supernus Pharmaceuticals shares in Q2 2026, an estimated $42.8K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #2958 holding.
  • Kestra Advisory Services first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Kestra Advisory Services's Supernus Pharmaceuticals position peaked at $357K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.